Home › Funds › Sanofi › IMRX

Sanofi position in IMRX

Immuneering Corp · Health Care

Sanofi reported holding 2,708,559 shares of IMRX (Immuneering Corp) in its Q3 2026 13F filing — a position valued at US$11.1M, representing 1.76% of its reported portfolio and ranking #12 among its reported holdings. Sanofi has disclosed IMRX holdings in 5 of the last 5 reported quarters, going back to Q3 2025.

Latest position (Q3 2026)2.71M sh
Reported value held$11.09M
Portfolio Weight1.76%
First reportedQ3 2025
Last changeHold
Updated2026-11-05

Last updated: 2026-11-05 · Source: SEC EDGAR Form 13F-HR

How Sanofi's IMRX position evolved

Sanofi first disclosed a stake in IMRX in Q3 2025 at 2,708,559 shares (US$19.0M). Across 5 filings, Sanofi held the position steady without any share-count change. The most recent filing (Q3 2026) shows 2,708,559 shares valued at US$11.1M.

Quarter by quarter

QuarterSharesValueChange
Q3 2025 2.71M $18.96M New
Q4 2025 2.71M $17.82M Hold
Q1 2026 2.71M $14.27M Hold
Q2 2026 2.71M $13.52M Hold
Q3 2026 2.71M $11.09M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About IMRX and 13F data

IMRX (Immuneering Corp) is a Health Care company. 59 other funds we track also report a position in IMRX — the largest reported positions include DCF Advisers, LLC (US$3.9M), ALETHEA CAPITAL MANAGEMENT, LLC (US$2.4M), Occam Crest Management LP (US$1.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding IMRX

All IMRX fund holders →

FAQ

How long has Sanofi held IMRX?

Sanofi has disclosed IMRX holdings in 5 of the last 5 reported quarters, going back to Q3 2025.

What is Sanofi's current position in IMRX?

As of Q3 2026, Sanofi holds 2.71M shares of IMRX (Immuneering Corp), valued at $11.09M, representing 1.76% of its reported portfolio and ranking #12.

Has Sanofi been buying or selling IMRX?

In the latest 13F filing (Q3 2026), Sanofi held unchanged its position in IMRX.

Which other funds hold IMRX?

Other major institutional holders of IMRX include DCF Advisers, LLC, ALETHEA CAPITAL MANAGEMENT, LLC, Occam Crest Management LP, among 59 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.